title: Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice.
abstract: TS-022, {4-[(1R, 2S, 3R, 5R)-5-Chloro-2-((S)-3-cyclohexyl-3-hydroxyprop-1-ynyl)-3-hydroxycyclopentyl] butylthio} acetic acid monohydrate, inhibits ADP-induced platelet aggregation, an effect significantly antagonized, as in the case of prostaglandin D(2) by the prostanoid DP(1) receptor antagonist (BW A868C). TS-022 is a prostanoid DP(1) receptor agonist, originally developed as a novel anti-pruritic drug for patients with atopic dermatitis. We examined the effects of TS-022 on experimental pruritus, cutaneous barrier disruption, and atopic dermatitis and in in vitro immune function tests. Topically applied TS-022 significantly suppressed scratching in skin-lesioned NC/Nga mice from a concentration of 2.5 nM, and this scratch-suppressive activity was significantly antagonized by BW A868C. Tacrolimus (FK-506) and dexamethasone, used as reference drugs for atopic dermatitis, also exhibited suppressive effects against scratching, but only at concentrations of 125 and 25,000 microM. TS-022 applied topically, once a day for 2 days, significantly accelerated repair of the cutaneous barrier disruption caused by mechanical scratching, from concentrations of 2.5 nM. This acceleration of repair of the disrupted cutaneous barrier by this drug was also significantly antagonized by BW A868C. FK-506 and dexamethasone showed no beneficial effects on the repair of the disrupted cutaneous barrier. Repeated topical application of 2.5 microM of TS-022 and 12.5 microM of FK-506 once a day for 6 weeks significantly improved the skin inflammation scores in the NC/Nga mice. In regard to the effects of TS-022 in vitro, the inhibitory activity of TS-022 against concanavalin A-induced cytokine production by splenocytes was marginal as compared with that of FK-506 or dexamethasone. These results suggest that the beneficial therapeutic effects of TS-022 in NC/Nga mice with atopic dermatitis are mediated by its suppressive effect on scratching and its effect of accelerating repair of the disrupted cutaneous barrier, both effects being attributable to its prostanoid DP(1) receptor agonistic activity.
authors.affiliation: Department of Pharmacology, Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan. i.arai@po.rd.taisho.co.jp
authors.forename: Iwao
authors.initials: I
authors.lastname: Arai
authors.forename: Akiko
authors.initials: A
authors.lastname: Takaoka
authors.forename: Yuki
authors.initials: Y
authors.lastname: Hashimoto
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Honma
authors.forename: Chie
authors.initials: C
authors.lastname: Koizumi
authors.forename: Nobuko
authors.initials: N
authors.lastname: Futaki
authors.forename: Masanori
authors.initials: M
authors.lastname: Sugimoto
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Takahashi
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Inoue
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Nakanishi
authors.forename: Takanobu
authors.initials: T
authors.lastname: Sakurai
authors.forename: Toru
authors.initials: T
authors.lastname: Tanami
authors.forename: Makoto
authors.initials: M
authors.lastname: Yagi
authors.forename: Naoya
authors.initials: N
authors.lastname: Ono
authors.forename: Shiro
authors.initials: S
authors.lastname: Nakaike
mesh_terms: D000085:Acetates / Q000494:pharmacology*; D000818:Animals; D000982:Antipruritics / Q000494:pharmacology*; D003208:Concanavalin A / Q000276:immunology; D003510:Cyclohexanes / Q000494:pharmacology*; D016207:Cytokines / Q000096:biosynthesis; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D003907:Dexamethasone / Q000494:pharmacology; D006801:Humans; D006827:Hydantoins / Q000494:pharmacology; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D008297:Male; D051379:Mice; D010974:Platelet Aggregation / Q000187:drug effects; D015230:Prostaglandin D2 / Q000378:metabolism; D011537:Pruritus / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D011971:Receptors, Immunologic / Q000819:agonists*; D011982:Receptors, Prostaglandin / Q000819:agonists*; D012867:Skin / Q000187:drug effects* / Q000276:immunology / Q000293:injuries; D013438:Sulfhydryl Compounds / Q000494:pharmacology*; D016559:Tacrolimus / Q000494:pharmacology; D014945:Wound Healing / Q000187:drug effects
chemical_list: C518544:(4-((1R, 2S, 3R, 5R)-5-Chloro-2-((S)-3-cyclohexyl-3-hydroxyprop-1-ynyl)-3-hydroxycyclopentyl) butylthio) acetic acid monohydrate; D000085:Acetates; D000982:Antipruritics; D003510:Cyclohexanes; D016207:Cytokines; D006827:Hydantoins; D007166:Immunosuppressive Agents; D011971:Receptors, Immunologic; D011982:Receptors, Prostaglandin; D013438:Sulfhydryl Compounds; D003208:Concanavalin A; C058848:BW A868C; D003907:Dexamethasone; D015230:Prostaglandin D2; D016559:Tacrolimus; C036293:prostaglandin D2 receptor